Skip to main content
OpenTrials
Completed

NCT Number: NCT01737840

Comparison of Pantoprazole and Ranitidine in Dyspepsia

The H0 hypothesis of the study is there is no difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department.

The H1 hypothesis is there is difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dyspepsia Disease Attributes Emergencies Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Akdeniz University

Antalya, 07050, Turkey (Türkiye)

About this study

Dyspepsia is one of the common complaints in emergency department. Proton pomp inhibitors, H2 receptor blockers and anti-acids are common drugs for treating dyspepsia in emergency department. However there is no study in the emergency department comparing the effectiveness of these drugs. So the investigators planned this study which drug is effective in these patients in order to provide a cost-effective treatment in dyspeptic patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Epigastric pain
  • Older than 18 years old

Exclusion criteria

  • Diagnosed as cholecystitis, pancreatitis, myocardial infarction, etc.. at the end of the emergency deparment evaluation period.
  • Pregnancy
  • Patients with unstable vital signs
  • Patients used anti-acid, H2 receptor blockers and proton pomp inhibitors in the last one hour.
  • Allergy to H2 receptor blockers and proton pomp inhibitors.
  • Patients denied to give inform consent and who are illiterate

Treatment and study plan

Pantoprazole

Drug

33 patients

Other names: Pantpas

Ranitidine

Drug

33 patients

Other names: Ulcuran

Primary outcomes

  1. Visual Analogue Scale Score

    Time frame: 30th and 60th minutes

    The investigators are measuring the change of pain from the baseline to the 30th and 60th minutes by visual anologue scale (VAS). Visual Analogue Scale measurement is between 0 (no pain) and 100 (worst pain). A decrease of 13 or 16 mm in VAS score is accepted as a minimum clinically significant change in pain.

Secondary outcomes

  1. Need for Additional Drug

    Time frame: 60 th minute

    The investigators are measuring the need for additional drug at the end of 60 minutes.

Sponsors and collaborators

Lead sponsor

Akdeniz University

Other

Registry information

Official study title

Intravenous Pantoprazole vs Ranitidine in Dyspepsia in Emergency Department: A Randomized Controlled Trial.

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Nov 30, 2012
Registry last updated
Jul 23, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.